Article

Gregory J. Riely on the Identification and Treatment of MET Exon 14 Skipping Mutations

Author(s):

Gregory J. Riely

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses identifying and treating patients with MET exon 14 skipping mutations in lung cancer.

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses identifying and treating patients with MET exon 14 skipping mutations in lung cancer.

Related Videos
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Image of man with grey hair.
Image of man with black hair.
Image of doctor with grey hair.
Image of doctor with black hair.
Related Content
Image of cancer vaccine.
March 25th 2025

New Cancer Vaccine, EVM14, Cleared for Investigational Drug Application

Spencer Feldman
EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Illustration of lungs.
March 25th 2025

First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer

Spencer Feldman
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small cell lung cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Treat lung diseases | Organ and pills on blue background top view | Image Credit: ©9dreamstudio - Adobe Stock
March 21st 2025

Understanding NCCN Guidelines: Gavreto in First-Line RET Fusion NSCLC

Spencer Feldman
Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, with potential severe side effects.
Illustration of doctor pointing at lungs.
March 20th 2025

Golidocitinib Plus PD-1 Antibodies Being Explored in Lung Cancer Subset

Alex Biese
Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will be presented this month.